44R0 Stock Overview

A a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. More details

44R0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 8.5% per year over past 5 years

Shares are highly illiquid

Does not have a meaningful market cap (€6M)

Makes less than USD$1m in revenue ($0)

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Phio Pharmaceuticals Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Phio Pharmaceuticals
Historical stock prices
Current Share Price	US$5.81
52 Week High	US$13.65
52 Week Low	US$3.14
Beta	1.53
1 Month Change	0%
3 Month Change	0.73%
1 Year Change	-57.42%
3 Year Change	-71.34%
5 Year Change	-99.59%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	44R0	DE Biotechs	DE Market
7D	0%	-1.4%	-0.9%
1Y	-57.4%	-12.5%	14.1%

Return vs Industry: 44R0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: 44R0 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 44R0's price volatile compared to industry and market?
44R0 volatility
44R0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.7%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 44R0 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 44R0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	10	Bob Bitterman	phiopharma.com

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy; PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in T and tumor cells; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

Phio Pharmaceuticals Corp. Fundamentals Summary

How do Phio Pharmaceuticals's earnings and revenue compare to its market cap?
44R0 fundamental statistics
Market cap	€5.27m
Earnings (TTM)	-€10.45m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is 44R0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
44R0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$154.00k
Gross Profit	-US$154.00k
Other Expenses	US$11.33m
Earnings	-US$11.48m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-7.63
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 44R0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/04/24 19:52
End of Day Share Price	2023/01/25 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Phio Pharmaceuticals Corp. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Maxim Jacobs	Edison Investment Research
Vernon Bernardino	H.C. Wainwright & Co.

44R0 Stock Overview

Risk Analysis

Phio Pharmaceuticals Corp. Competitors

4SC

co.don

Medigene

bioXXmed

Price History & Performance

Recent News & Updates

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762

Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.83 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $2.500005 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $0.48 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.152001 million.

Recent updates

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762

Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.83 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $2.500005 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $0.48 million.

Phio Pharmaceuticals Corp. has filed a Follow-on Equity Offering in the amount of $1.152001 million.

Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research

Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer

Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894

Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding

Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals Corp. Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

Phio Pharmaceuticals Discloses Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Presents New Data Demonstrating PH-894 Enhances Activity of Her2-Car T Cells At ASGCT 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Phio Pharmaceuticals Corp. Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at AACR Annual Meeting 2022

Phio Pharmaceuticals Corp. Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

Phio Pharmaceuticals and AgonOx Inc. Announces Collaboration on Clinical Development of Novel T Cell-Based Cancer Immunotherapies

Phio Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $7.684001 million.

Phio Pharmaceuticals Corp. announced that it has received $14.001908 million in funding

Phio Pharmaceuticals Corp. announced that it expects to receive $14.002049 million in funding

Phio Pharmaceuticals Corp. Announces Positive in Vivo Data on Combination PD-1 and TIGIT Checkpoint Blockade with INTASYL in a Single Therapeutic for Cancer Treatment